Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTx-758 in Castration Resistant Prostate Cancer
NCT01420861Phase 2Terminated
- Sponsor
- GTx
- Start
- Sep 2011
- Primary completion
- Dec 2012
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GTx-758 in prostate cancer (PCa), sponsored by GTx. Primary endpoint: Decline in Serum Prostate-specific antigen at 30 days. Started Sep 2011; status: terminated.
02
Drugs
GTx-758
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01420861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420861.